Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US

Michele Jara,1 Graham Barker,2 Herbert R Henney 3rd1 1Acorda Therapeutics, Inc, Ardsley, NY, USA; 2Biogen Idec, Inc, Maidenhead, Berkshire, UK Background: Dalfampridine extended release tablets (dalfampridine-ER; prolonged-, modified, or sustained-release fampridine in some countries) were approved...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jara M, Barker G, Henney 3rd HR
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2013
Materias:
Acceso en línea:https://doaj.org/article/2af4b1c328f540d0b209d4c8a88d0535
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!